Results 171 to 180 of about 6,598 (226)

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study

Francesca Lucca, Ilaria Meneghelli, Gloria Tridello, Francesca Buniotto, Giulia Cucchetto, Sonia Volpi, Emily Pintani, Valentino Bezzerri, Marco Cipolli   +8 more
openalex   +2 more sources

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports. [PDF]

Respir Med Case Rep
van Mourik P, van der Hout EC, Luijk HD, Hofland RW, Bruns AHW, Heijerman HGM, Bronsveld I.   +6 more
europepmc   +1 more source

Acute cholecystitis as an adverse effect of treatment with elexacaftor/tezacaftor/ivacaftor in a patient with cystic fibrosis

Carlos Martín de Vicente, Silvia Jade Cáceres Barrera, Sánchez González, Cristina Alonso, Ruth García Romero   +4 more
openalex   +1 more source

Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]

Am J Respir Crit Care Med
Wilson G, Hughes D.
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Muscle Composition in Cystic Fibrosis: An AI-Assisted Chest CT-Based Body Composition Analysis. [PDF]

Med Sci (Basel)
Welsner M, Stehling F, Gruber W, Westhölter D, Sutharsan S, Taube C, Büscher E, Nensa F, Zensen S, Umutlu L, Forsting M, Haubold J, Salhöfer L, Holtkamp M, Kohnke J, Hosch R, Opitz M.   +16 more
europepmc   +1 more source

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study. [PDF]

Life (Basel)
Tosto M, Parisi GF, Presti S, Papale M, Pecora G, Mulè E, Ornato V, Aloisio D, Manti S, Leonardi S.   +9 more
europepmc   +1 more source

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy [PDF]

Danni Li, Martin Donnelley, David Parsons, Mark D. Habgood, Elena K. Schneider‐Futschik   +4 more
openalex   +1 more source

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. [PDF]

Clin Transl Sci
Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P, Poscia R, Cimino G.   +7 more
europepmc   +1 more source

Elexacaftor-tezacaftor-ivacaftor and cystic fibrosis liver disease: A turning point that calls for cautious optimism. [PDF]

JHEP Rep
Rautou PE, Hillaire S, Gambazza S, Colombo C.   +3 more
europepmc   +1 more source

Development and Validation of a New LC-MS/MS Method for Simultaneous Quantification of Ivacaftor, Tezacaftor and Elexacaftor Plasma Levels in Pediatric Cystic Fibrosis Patients. [PDF]

Pharmaceuticals (Basel)
Mancini A, Simeoli R, Cristiani L, Cairoli S, Ciciriello F, Boni A, Alghisi F, Rossi C, Antonetti G, Vici CD, Fiocchi AG, Cutrera R, Goffredo BM.   +12 more
europepmc   +1 more source